Hematology

Publications

Alharbi, S; Merkle, S; Hammill, AM; Waters, AM; Le Cras, TD. RAS Pathway Mutations and Therapeutics in Vascular Anomalies. Pediatric Blood and Cancer. 2025; 72:e31605.

Ambrose, EE; Sabuni, PA; Jason, DP; Ware, RE; Makubi, AN; Smart, LR. Hydroxyurea to decrease stroke risk in children with sickle cell anemia: a systematic review and meta-analysis. 2025; 1:100001.

Boucher, AA; Dayton, VJ; Pratt, AR; Nassar, NN; Elgammal, Y; Kalfa, TA. Three-generation female cohort with macrocytic anemia and iron overload. American Journal of Hematology. 2025; 100:133-138.

Canaud, G; López-Gutiérrez, JC; Hammill, A; Weibel, L; Niglis, S; Paul, M; Papadimitriou, A; Wroclawska, M; Caro, N; Adams, D. 118: Randomized, Double-Blind, Phase 2 Study of Alpelisib in Pediatric and Adult Patients With PIK3CA-Related Overgrowth Spectrum (PROS). Journal of Investigative Dermatology. 2025; 145:e29.

Cantrell, R; Alex Feldman, H; Rosenfeldt, L; Ali, A; Gourley, B; Sprague, C; Leino, D; Crosby, J; Revenko, A; Monia, B; Waggoner, SN; Palumbo, JS. Prothrombin prevents fatal T cell-dependent anemia during chronic virus infection of mice. JCI insight. 2025; 10:e181063.

Chan, AK; Susen, S; Khoo, L; von Drygalski, A; Oldenburg, J; Shen, M; Peyvandi, F; Tarango, C; Chowdary, P; Mamikonian, L; Palmborg, H; Dumont, J; Santagostino, E; Hermans, C. Perioperative Management with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Hemophilia A in the Phase 3 XTEND Clinical Program. Hamostaseologie. 2025; 45:s57-s58.

Coleman, KD; McKinley, K; Ellison, AM; Alpern, ER; Hariharan, S; Topoz, I; Wurtz, M; Nielsen, B; Cook, LJ; Morris, CR; King, AA; Baumann, A; Frankenberger, W; Brousseau, DC. Associations Between Pain Scores and Opioid Doses With Emergency Department Disposition and Return Visit Rates in Children With Sickle Cell Disease. Pediatric Blood and Cancer. 2025; e31750.

Costa, E; Ware, RE; Tshilolo, L; Makani, J; Leufkens, HG M; Luzzatto, L. Globalization in clinical drug development for sickle cell disease. American Journal of Hematology. 2025; 100:4-9.

Davies, SM; Grimley, MS; Shrestha, A; Shova, A; Asnani, M; Kent, M; Sayani, F; Quinn, CT; Niss, O; Lutzko, CM; Witting, S; Latham, T; Bushman, FD; Malik, P. Gene Therapy with Reduced-Intensity Conditioning for Sickle Cell Disease. Transplantation and Cellular Therapy. 2025; 31:s2-s3.

Dei-Adomakoh, YA; Segbefia, CI; Latham, TS; Lane, AC; Dzefi-Tettey, K; Amissah-Arthur, K; Corquaye, O; Korang, L; Mensah, E; Ekpale, P; Seedah, D; Stuber, SE; Smart, LR; Ware, RE. Hydroxyurea for Children and Adults with Hemoglobin SC Disease. 2025; 4:EVIDoa2400402.

Engel, ER; Luchtman-Jones, L. Comment on: "Comment on: Bivalirudin During Thrombolysis With Catheter-Directed tPA in a Heparin-Refractory Patient: A Case Report ": The Promise of Dilute Thrombin Time and Drug-Calibrated Assays for Improved Bivalirudin Monitoring. Pediatric Blood and Cancer. 2025; 72:e31418.

Goldenberg, NA; Schulman, S; Kittelson, JM; Abshire, TC; Casella, JF; Dale, R; Halperin, JL; Hanson, J; Kessler, CM; Manco-Johnson, MJ; McDevitt, L; Sidonio, RF; Spyropoulos, AC; Steg, PG; Bonaca, MP. Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years. Journal of Thrombosis and Haemostasis. 2025; 23:651-656.

Haacker, L; Littner, L; Martin, M; Brokamp, C; Beck, AF; Luchtman-Jones, L. Reply to: Comment on Anemia in Young Children and the Association With Socioeconomic Deprivation Indices. Pediatric Blood and Cancer. 2025; e31743.

Haacker, L; Littner, L; Martin, M; Brokamp, C; Beck, AF; Luchtman-Jones, L. Anemia in Young Children and the Association With Socioeconomic Deprivation Indices. Pediatric Blood and Cancer. 2025; e31663.

Hau, DK; Fadhil, S; Lee, MH; Desderius, B; Willkens, M; Kalluvya, SE; Tebuka, E; Smart, LR; Peck, RN. Causes and Consequences of Persistent Anemia after 6 Months of Antiretroviral Therapy in Tanzania: An Observational Comparative Cohort Study. American Journal of Tropical Medicine and Hygiene. 2025; 112:234-241.

Hildenbrand, AK; Mara, CA; Murphy, B; Hood, AM; Johnson, Y; Shook, LM; Real, FJ; Nwankwo, C; Hackworth, R; Badawy, SM; Saving, KL; Treadwell, M; Quinn, CT; Crosby, LE. Engaging Parents of Children With Sickle Cell Disease in Shared Decision-Making for Hydroxyurea: The ENGAGE-HU Study. Pediatric Blood and Cancer. 2025; 72:e31639.

Littner, L; Thomas, E; Mooney, L; Doyle, J; Hendrickson, J; Tarango, C. Improving Time to Bleeding Disorder Treatment in the Emergency Department. Pediatric Blood and Cancer. 2025; 72:e31570.

Nayak, RC; Emberesh, S; Trump, LR; Wellendorf, AM; Singh, AK; Korkmaz, B; Horwitz, MS; Myers, KC; Kalfa, TA; Lutzko, CM; Cancelas, JA. G-CSF resistance of ELANE-mutant neutropenia depends on SERF1-containing truncated-neutrophil elastase aggregates. The Journal of Clinical Investigation. 2025; 135:e177342.

Nieves, RM; Latham, T; Marte, N; Berges, M; Sánchez, LM; Urcuyo, G; Florencio, C; Gonzalez, C; del Villar, P; Chen, S; Schultz, WH; Lane, AC; Mena, R; Ware, RE. Stroke prevention in Hispanic children with sickle cell anemia: the SACRED trial. Blood Advances. 2025; 9:1791-1800.

Power-Hays, A; Namazzi, R; Kato, C; McElhinney, KE; Conroy, AL; Hume, H; John, C; O'Hara, SM; Stuber, SE; Lane, A; Latham, TS; Opoka, RO; Ware, RE. Pharmacokinetic-Guided Hydroxyurea to Reduce Transfusions in Ugandan Children with Sickle Cell Anemia: Study Design of the Alternative Dosing And Prevention of Transfusions Trial. Acta Haematologica. 2025; 148:208-219.

Quinn, CT; Ware, RE. The modern use of hydroxyurea for children with sickle cell anemia. Haematologica: the hematology journal. 2025; 110:1061-1073.

Quinn, CT; Ware, RE. The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease?. Pediatric Blood and Cancer. 2025; 72:e31475.

Richmond, A; Hansen, S; Dykman, M; Adams, DM; Antaya, RJ; Bennett, JT; Frieden, IJ; Hammill, AM; Liang, MG; Maheshwari, M; Chamlin, S; Cotton, C; Lalor, L; Lee, LW. 44: Capillary Malformation-Arteriovenous Malformation Syndrome: Proposed Consensus Guidelines. Journal of Investigative Dermatology. 2025; 145:e12.

Rineer, S; Kwakye, D; Ambrose, EE; Jason, ID P; Smart, LR. Validation of Pediatric Self-Report Pain Scales in Sub-Saharan Africa: A Systematic Review. Journal of Pain and Symptom Management. 2025; 69:e103-e112.

Shook, LM; Haygood, D; Quinn, CT. Clinical Utility of the Addition of Molecular Genetic Testing to Newborn Screening for Hemoglobinopathies for Confirmation of Alpha-Thalassemia Trait. International Journal of Neonatal Screening. 2025; 11:12.

Shook, LM; House, B; Farrell, CB; Stewart, R; Lanzkron, S; King, AA; Varughese, T; Strouse, JJ; Treadwell, M; Kanter, J. Challenges of Engaging Primary Care Providers in Specialized Telementoring Education About Sickle Cell Disease for Sickle Cell Specialists: Results from the Sickle Cell Disease Training and Mentoring Program for Primary Care Providers (STAMP) Project ECHO. AJPM Focus. 2025; 4:100304.

Sisk, BA; Eng, W; Aye, J; Mack, J; Tran, A; Ogino, J; Pearson, E; Bies, J; Smink, G; Shah, SD; Echols, T; Kumar, S; Fox, M; King, KA. Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States. Pediatric Blood and Cancer. 2025; 72:e31661.

Todd, K; Hogue, SJ; Tweddell, JS; Reagor, JA; Mullins, E; Block, MG; Rosenfeldt, L; Francisco, B; Jodele, S; Sharma, BK; Lane, A; Slusher, C; Kharnaf, M; Morales, DL S; Palumbo, JS. Hemostatic derangements associated with cardiopulmonary bypass predict outcomes in pediatric patients undergoing corrective heart surgery. Journal of Thrombosis and Haemostasis. 2025; 23:492-503.

Vore, E; Cooke-Barber, J; Brungardt, J; Tiao, G; Hammill, A; Ricci, K; Patel, M; Dasgupta, R. Management, Trends, and Recommendations for Intra-abdominal Lymphatic Malformations: A Single-Center Retrospective Review. Journal of Pediatric Surgery. 2025; 60:162223.

Wilson, HP; Mosha, M; Miller, A; Betensky, M; Amankwah, E; Fargo, J; Thornburg, CD; Tarango, C; Acharya, S; Male, C; Narang, S; Schulman, S; Goldenberg, NA. Secondary Anticoagulation Use in Patients < 21 Years Old following Primary Anticoagulant Treatment for Provoked Venous Thromboembolism: Findings from the Kids-DOTT Trial. Seminars in Thrombosis and Hemostasis. 2025; 51:343-347.

Zia, A; Nelson, MD; Ren, J; Zhang, S; Mattrey, RF; Han, BL; Hussain, T; Greer, JS; Al-Qahtani, M; Malone, K; Woodward, RS; Levine, B; Klok, FA; Rajpurkar, M. The Functional Characterization of Venous Thromboembolic Disease (FUVID) study: rationale, design, and methods of a prospective, observational, multicenter study to evaluate mechanisms of exercise intolerance and dyspnea following pediatric pulmonary embolism. Research and Practice in Thrombosis and Haemostasis. 2025; 9:102669.